Peripheral Vascular Diseases Clinical Trial
— STEMPADOfficial title:
Pilot Study of Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease (STEMPAD Trial)
This study is designed to test the use of G-CSF in peripheral vascular disease. The investigators hypothesize that mobilization of angiogenic cells into the blood by granulocyte colony stimulating factor (G-CSF) may stimulate the formation of new blood vessels and result in a sustained improvement in blood flow in patients with severe peripheral arterial disease.
Status | Completed |
Enrollment | 32 |
Est. completion date | April 2012 |
Est. primary completion date | April 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients must have critical limb ischemia secondary to PAD, as defined by the presence of a non-healing ulcer, rest pain, or dry gangrene. - Patients must have a toe pressure = 30 mm Hg. - Patients must be =18 years old. - Patient must be able to self-administer a daily subcutaneous injection or have a caregiver who is able to administer a daily subcutaneous injection. - Patients must be taking or have no absolute contraindication to taking aspirin and clopidogrel. If they are not currently taking aspirin, they must be willing to take aspirin (81 mg daily) and clopidogrel (75 mg daily) for 14 days starting on the first day of G-CSF treatment. - After being informed of the treatment involved, patients must give written consent. The patient should not have any serious medical or psychiatric illness that would prevent either the giving of informed consent or the receipt of treatment. A built-in period of one week from discussion of the trial and initiation of the trial will be mandatory for enrollment. Exclusion Criteria: - Patients with transmetatarsal or higher amputations in the affected limb are excluded. - Patients who are candidates for a revascularization procedure. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Washington University School of Medicine | St. Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Major limb amputation rate as defined by amputations of the limb that are transmetarsal and higher | 1 year | No | |
Secondary | Toe pressure index | Toe brachial index (TBI) and is a calculation based on the systolic blood pressures of the arm and the systolic blood pressures of the toes. The examination is performed with a photoplethysmograph (PPG) infrared light sensor and a very small blood pressure cuff placed around the toe. The arm and big toe systolic blood pressure measurements are recorded. Then the big toe systolic pressures are divided by the highest arm pressure to establish an TBI measurement for each leg. A TBI of .75 or greater is consider normal. |
Up to 1 year | No |
Secondary | Ankle-brachial index | The Ankle Brachial Index (ABI or ABPI) is the ratio of the blood pressure in the lower legs to the blood pressure in the arms. Compared to the arm, lower blood pressure in the leg is an indication of blocked arteries (peripheral vascular disease or PVD). The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm. A normal resting ankle-brachial index is 1 or 1.1. A resting ankle-brachial index of less than 1 is abnormal. If the ABI is: Less than 0.95, significant narrowing of one or more blood vessels in the legs is indicated. Less than 0.8, pain in the foot, leg, or buttock may occur during exercise (intermittent claudication). Less than 0.4, symptoms may occur when at rest. 0.25 or below, severe limb-threatening peripheral artery disease is probably present. |
Up to 1 year | No |
Secondary | Ulcer healing as measured by surface area and depth | Skin ulcerations should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeat measurements. A maximum of 3 ulcers on each lower extremity will be followed. An average of the longest diameter for all ulcerations will be calculated and reported as the baseline average longest diameter. The baseline average will be used as reference by which to characterize the ulcerations. |
Up to 1 year | No |
Secondary | Improvement in rest pain as measured by the Vascular Quality of Life Questionnaire | -25 questions including questions in activity, symptom, pain, emotional, and social domains. Each question has seven choices ranging from "All" to "None" Each domain is scored 1-7=the total of domain item scores divided by the number of questions in the domain. The total score is is also scored 1-7=the total of all the item scores divided by 25. |
Up to 1 year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Completed |
NCT00536796 -
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
|
N/A | |
Completed |
NCT00371371 -
Intra-arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia (CLI)
|
Phase 1/Phase 2 | |
Recruiting |
NCT00173602 -
The Burden of Peripheral Artery Occlusion Disease and Associated Factors in Peritoneal Dialysis Patients
|
N/A | |
Completed |
NCT00163267 -
Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel
|
Phase 2/Phase 3 | |
Completed |
NCT00228384 -
GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
|
Phase 4 | |
Completed |
NCT00106327 -
Improving Functioning in Peripheral Arterial Disease
|
N/A | |
Completed |
NCT00049907 -
Cardiac and Renal Disease Study (CARDS)
|
N/A | |
Completed |
NCT00000614 -
Prevention of Recurrent Venous Thromboembolism (PREVENT)
|
Phase 3 | |
Completed |
NCT00005392 -
Epidemiology of Venous Disease
|
N/A | |
Recruiting |
NCT05596760 -
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
|
N/A | |
Recruiting |
NCT00539266 -
Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia
|
Phase 2/Phase 3 | |
Completed |
NCT00541307 -
GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)
|
N/A | |
Completed |
NCT00520312 -
Magnetic Resonance Imaging to Identify Characteristics of Plaque Build-Up in People With Peripheral Arterial Disease
|
N/A | |
Terminated |
NCT00504088 -
Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia
|
Phase 4 | |
Completed |
NCT00533104 -
Cell Therapy in Chronic Limb Ischemia
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05459818 -
Individual Patient Data Analysis of Viabahn for Peripheral Arterial Disease
|
||
Completed |
NCT03875846 -
Intraoperative Simultaneous Pressure Guided Revascularization Study
|
||
Active, not recruiting |
NCT05110677 -
Pilot Study of Topographic Imaging of the Calf Muscle in Patients With PAD Using 3D Reconstruction of MSOT Images
|
||
Active, not recruiting |
NCT02856230 -
An Efficacy and Safety Study to Evaluate Ranger DEB for BTK Angioplasty in Patients With CLI (RANGER-BTK)
|
Phase 2/Phase 3 |